ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Research Report 2025
Published Date: May 2025
|
Report Code: QYRE-Auto-8C15900
Home | Market Reports | Health| Health Conditions
Global Paroxysmal Nocturnal Hemoglobinuria PNH Treatment Market Research Report 2023
BUY CHAPTERS

Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Research Report 2025

Code: QYRE-Auto-8C15900
Report
May 2025
Pages:93
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
EIPICO
Minapharm Pharmaceuticals
Pharco Pharmaceuticals
Alexion Pharmaceuticals
Alnylam Pharmaceuticals
Akari Therapeutics
CSL Behring
Bioverativ
F Hoffmann La Roche Ltd
Novartis
Teva Pharmaceutical
Abbott
Amoun Pharmaceuticals
Amgen Inc

Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Size

The global market for Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment was valued at US$ 122 million in the year 2024 and is projected to reach a revised size of US$ 251 million by 2031, growing at a CAGR of 11.0% during the forecast period.

Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market

Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market

Paroxysmal nocturnal hemoglobinuria (PNH) is a non-malignant clonal disease caused by acquired somatic PIG-A gene (phosphotidyl inositol glycan complementation group A) mutations in one or several hematopoietic stem cells. Disease, PIG-A mutation causes abnormal synthesis of glycosyl phosphatidyl inositol (GPI), resulting in the loss of a group of membrane proteins anchored to the cell membrane by GPI, including CD16, CD55, CD59, etc., which are mainly clinically It manifests as chronic intravascular hemolysis, hematopoietic failure and recurrent thrombosis.
The paroxysmal nocturnal hemoglobinuria (PNH) treatment market is a growing area focused on developing innovative drugs and treatments to improve the quality of life of patients with PNH. The market covers various treatment options, including monoclonal antibody therapies, immunosuppressive drugs, and hematopoietic stem cell transplantation, aimed at alleviating symptoms, controlling hemolysis, and improving blood abnormalities in PNH patients, thus providing better clinical outcomes. As scientific research continues to advance and medical technology continues to improve, the PNH treatment market is expected to continue to expand, providing patients with more treatment options and the opportunity to improve survival rates.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment.
The Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Report

Report Metric Details
Report Name Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market
Accounted market size in year US$ 122 million
Forecasted market size in 2031 US$ 251 million
CAGR 11.0%
Base Year year
Forecasted years 2025 - 2031
Segment by Type
  • Monoclonal Antibodies Therapy
  • Immunosuppressive Drugs
  • Hematopoietic Stem Cell Transplantation
Segment by Application
  • Hospital
  • Clinic
  • Other
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company Amoun Pharmaceuticals, EIPICO, Minapharm Pharmaceuticals, Pharco Pharmaceuticals, Alexion Pharmaceuticals, Alnylam Pharmaceuticals, Akari Therapeutics, Amgen, CSL Behring, Bioverativ, F. Hoffmann-La Roche Ltd, Novartis AG, Amgen Inc, Teva Pharmaceutical, Abbott
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Detailed analysis of Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Sales, revenue of Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 9: The main points and conclusions of the report. 

FAQ for this report

How fast is Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market growing?

Ans: The Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market witnessing a CAGR of 11.0% during the forecast period 2025-2031.

What is the Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market size in 2031?

Ans: The Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market size in 2031 will be US$ 251 million.

Who are the main players in the Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market report?

Ans: The main players in the Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market are Amoun Pharmaceuticals, EIPICO, Minapharm Pharmaceuticals, Pharco Pharmaceuticals, Alexion Pharmaceuticals, Alnylam Pharmaceuticals, Akari Therapeutics, Amgen, CSL Behring, Bioverativ, F. Hoffmann-La Roche Ltd, Novartis AG, Amgen Inc, Teva Pharmaceutical, Abbott

What are the Application segmentation covered in the Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market report?

Ans: The Applications covered in the Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market report are Hospital, Clinic, Other

What are the Type segmentation covered in the Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market report?

Ans: The Types covered in the Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market report are Monoclonal Antibodies Therapy, Immunosuppressive Drugs, Hematopoietic Stem Cell Transplantation

1 Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Overview
1.1 Product Definition
1.2 Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment by Type
1.2.1 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Value Comparison by Type (2024 VS 2031)
1.2.2 Monoclonal Antibodies Therapy
1.2.3 Immunosuppressive Drugs
1.2.4 Hematopoietic Stem Cell Transplantation
1.3 Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment by Application
1.3.1 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Value by Application (2024 VS 2031)
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Other
1.4 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Size Estimates and Forecasts
1.4.1 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue 2020-2031
1.4.2 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales 2020-2031
1.4.3 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Average Price (2020-2031)
1.5 Assumptions and Limitations
2 Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Competition by Manufacturers
2.1 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales Market Share by Manufacturers (2020-2025)
2.2 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue Market Share by Manufacturers (2020-2025)
2.3 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment, Product Type & Application
2.7 Global Key Manufacturers of Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment, Date of Enter into This Industry
2.8 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Competitive Situation and Trends
2.8.1 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Players Market Share by Revenue
2.8.3 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Scenario by Region
3.1 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales by Region: 2020-2031
3.2.1 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales by Region: 2020-2025
3.2.2 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales by Region: 2026-2031
3.3 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue by Region: 2020-2031
3.3.1 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue by Region: 2020-2025
3.3.2 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue by Region: 2026-2031
3.4 North America Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Facts & Figures by Country
3.4.1 North America Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales by Country (2020-2031)
3.4.3 North America Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue by Country (2020-2031)
3.4.4 United States
3.4.5 Canada
3.5 Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Facts & Figures by Country
3.5.1 Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales by Country (2020-2031)
3.5.3 Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Facts & Figures by Region
3.6.1 Asia Pacific Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales by Region (2020-2031)
3.6.3 Asia Pacific Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Facts & Figures by Country
3.7.1 Latin America Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales by Country (2020-2031)
3.7.3 Latin America Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Facts & Figures by Country
3.8.1 Middle East and Africa Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales by Country (2020-2031)
3.8.3 Middle East and Africa Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales by Type (2020-2031)
4.1.1 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales by Type (2020-2025)
4.1.2 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales by Type (2026-2031)
4.1.3 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales Market Share by Type (2020-2031)
4.2 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue by Type (2020-2031)
4.2.1 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue by Type (2020-2025)
4.2.2 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue by Type (2026-2031)
4.2.3 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue Market Share by Type (2020-2031)
4.3 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Price by Type (2020-2031)
5 Segment by Application
5.1 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales by Application (2020-2031)
5.1.1 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales by Application (2020-2025)
5.1.2 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales by Application (2026-2031)
5.1.3 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales Market Share by Application (2020-2031)
5.2 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue by Application (2020-2031)
5.2.1 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue by Application (2020-2025)
5.2.2 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue by Application (2026-2031)
5.2.3 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue Market Share by Application (2020-2031)
5.3 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Price by Application (2020-2031)
6 Key Companies Profiled
6.1 Amoun Pharmaceuticals
6.1.1 Amoun Pharmaceuticals Company Information
6.1.2 Amoun Pharmaceuticals Description and Business Overview
6.1.3 Amoun Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales, Revenue and Gross Margin (2020-2025)
6.1.4 Amoun Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Product Portfolio
6.1.5 Amoun Pharmaceuticals Recent Developments/Updates
6.2 EIPICO
6.2.1 EIPICO Company Information
6.2.2 EIPICO Description and Business Overview
6.2.3 EIPICO Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales, Revenue and Gross Margin (2020-2025)
6.2.4 EIPICO Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Product Portfolio
6.2.5 EIPICO Recent Developments/Updates
6.3 Minapharm Pharmaceuticals
6.3.1 Minapharm Pharmaceuticals Company Information
6.3.2 Minapharm Pharmaceuticals Description and Business Overview
6.3.3 Minapharm Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales, Revenue and Gross Margin (2020-2025)
6.3.4 Minapharm Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Product Portfolio
6.3.5 Minapharm Pharmaceuticals Recent Developments/Updates
6.4 Pharco Pharmaceuticals
6.4.1 Pharco Pharmaceuticals Company Information
6.4.2 Pharco Pharmaceuticals Description and Business Overview
6.4.3 Pharco Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales, Revenue and Gross Margin (2020-2025)
6.4.4 Pharco Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Product Portfolio
6.4.5 Pharco Pharmaceuticals Recent Developments/Updates
6.5 Alexion Pharmaceuticals
6.5.1 Alexion Pharmaceuticals Company Information
6.5.2 Alexion Pharmaceuticals Description and Business Overview
6.5.3 Alexion Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales, Revenue and Gross Margin (2020-2025)
6.5.4 Alexion Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Product Portfolio
6.5.5 Alexion Pharmaceuticals Recent Developments/Updates
6.6 Alnylam Pharmaceuticals
6.6.1 Alnylam Pharmaceuticals Company Information
6.6.2 Alnylam Pharmaceuticals Description and Business Overview
6.6.3 Alnylam Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales, Revenue and Gross Margin (2020-2025)
6.6.4 Alnylam Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Product Portfolio
6.6.5 Alnylam Pharmaceuticals Recent Developments/Updates
6.7 Akari Therapeutics
6.7.1 Akari Therapeutics Company Information
6.7.2 Akari Therapeutics Description and Business Overview
6.7.3 Akari Therapeutics Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales, Revenue and Gross Margin (2020-2025)
6.7.4 Akari Therapeutics Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Product Portfolio
6.7.5 Akari Therapeutics Recent Developments/Updates
6.8 Amgen
6.8.1 Amgen Company Information
6.8.2 Amgen Description and Business Overview
6.8.3 Amgen Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales, Revenue and Gross Margin (2020-2025)
6.8.4 Amgen Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Product Portfolio
6.8.5 Amgen Recent Developments/Updates
6.9 CSL Behring
6.9.1 CSL Behring Company Information
6.9.2 CSL Behring Description and Business Overview
6.9.3 CSL Behring Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales, Revenue and Gross Margin (2020-2025)
6.9.4 CSL Behring Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Product Portfolio
6.9.5 CSL Behring Recent Developments/Updates
6.10 Bioverativ
6.10.1 Bioverativ Company Information
6.10.2 Bioverativ Description and Business Overview
6.10.3 Bioverativ Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales, Revenue and Gross Margin (2020-2025)
6.10.4 Bioverativ Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Product Portfolio
6.10.5 Bioverativ Recent Developments/Updates
6.11 F. Hoffmann-La Roche Ltd
6.11.1 F. Hoffmann-La Roche Ltd Company Information
6.11.2 F. Hoffmann-La Roche Ltd Description and Business Overview
6.11.3 F. Hoffmann-La Roche Ltd Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales, Revenue and Gross Margin (2020-2025)
6.11.4 F. Hoffmann-La Roche Ltd Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Product Portfolio
6.11.5 F. Hoffmann-La Roche Ltd Recent Developments/Updates
6.12 Novartis AG
6.12.1 Novartis AG Company Information
6.12.2 Novartis AG Description and Business Overview
6.12.3 Novartis AG Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales, Revenue and Gross Margin (2020-2025)
6.12.4 Novartis AG Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Product Portfolio
6.12.5 Novartis AG Recent Developments/Updates
6.13 Amgen Inc
6.13.1 Amgen Inc Company Information
6.13.2 Amgen Inc Description and Business Overview
6.13.3 Amgen Inc Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales, Revenue and Gross Margin (2020-2025)
6.13.4 Amgen Inc Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Product Portfolio
6.13.5 Amgen Inc Recent Developments/Updates
6.14 Teva Pharmaceutical
6.14.1 Teva Pharmaceutical Company Information
6.14.2 Teva Pharmaceutical Description and Business Overview
6.14.3 Teva Pharmaceutical Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales, Revenue and Gross Margin (2020-2025)
6.14.4 Teva Pharmaceutical Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Product Portfolio
6.14.5 Teva Pharmaceutical Recent Developments/Updates
6.15 Abbott
6.15.1 Abbott Company Information
6.15.2 Abbott Description and Business Overview
6.15.3 Abbott Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales, Revenue and Gross Margin (2020-2025)
6.15.4 Abbott Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Product Portfolio
6.15.5 Abbott Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Industry Chain Analysis
7.2 Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Production Mode & Process Analysis
7.4 Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales and Marketing
7.4.1 Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales Channels
7.4.2 Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Distributors
7.5 Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Customer Analysis
8 Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Dynamics
8.1 Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Industry Trends
8.2 Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Drivers
8.3 Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Challenges
8.4 Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
FEATURED COMPANIES
EIPICO
Minapharm Pharmaceuticals
Pharco Pharmaceuticals
Alexion Pharmaceuticals
Alnylam Pharmaceuticals
Akari Therapeutics
CSL Behring
Bioverativ
F Hoffmann La Roche Ltd
Novartis
Teva Pharmaceutical
Abbott
Amoun Pharmaceuticals
Amgen Inc
List of Tables
 Table 1. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Value Comparison by Type (2024 VS 2031) & (US$ Million)
 Table 2. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Value by Application (2024 VS 2031) & (US$ Million)
 Table 3. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Competitive Situation by Manufacturers in 2024
 Table 4. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales (K Units) of Key Manufacturers (2020-2025)
 Table 5. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales Market Share by Manufacturers (2020-2025)
 Table 6. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue (US$ Million) by Manufacturers (2020-2025)
 Table 7. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue Share by Manufacturers (2020-2025)
 Table 8. Global Market Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Average Price (US$/Unit) of Key Manufacturers (2020-2025)
 Table 9. Global Key Players of Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment, Industry Ranking, 2022 VS 2023 VS 2024
 Table 10. Global Key Manufacturers of Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment, Manufacturing Sites & Headquarters
 Table 11. Global Key Manufacturers of Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment, Product Type & Application
 Table 12. Global Key Manufacturers of Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment, Date of Enter into This Industry
 Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 14. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment as of 2024)
 Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
 Table 16. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 17. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales by Region (2020-2025) & (K Units)
 Table 18. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales Market Share by Region (2020-2025)
 Table 19. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales by Region (2026-2031) & (K Units)
 Table 20. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales Market Share by Region (2026-2031)
 Table 21. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue by Region (2020-2025) & (US$ Million)
 Table 22. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue Market Share by Region (2020-2025)
 Table 23. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue by Region (2026-2031) & (US$ Million)
 Table 24. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue Market Share by Region (2026-2031)
 Table 25. North America Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 26. North America Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales by Country (2020-2025) & (K Units)
 Table 27. North America Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales by Country (2026-2031) & (K Units)
 Table 28. North America Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue by Country (2020-2025) & (US$ Million)
 Table 29. North America Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue by Country (2026-2031) & (US$ Million)
 Table 30. Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 31. Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales by Country (2020-2025) & (K Units)
 Table 32. Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales by Country (2026-2031) & (K Units)
 Table 33. Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue by Country (2020-2025) & (US$ Million)
 Table 34. Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue by Country (2026-2031) & (US$ Million)
 Table 35. Asia Pacific Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 36. Asia Pacific Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales by Region (2020-2025) & (K Units)
 Table 37. Asia Pacific Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales by Region (2026-2031) & (K Units)
 Table 38. Asia Pacific Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue by Region (2020-2025) & (US$ Million)
 Table 39. Asia Pacific Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue by Region (2026-2031) & (US$ Million)
 Table 40. Latin America Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 41. Latin America Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales by Country (2020-2025) & (K Units)
 Table 42. Latin America Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales by Country (2026-2031) & (K Units)
 Table 43. Latin America Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue by Country (2020-2025) & (US$ Million)
 Table 44. Latin America Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue by Country (2026-2031) & (US$ Million)
 Table 45. Middle East and Africa Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 46. Middle East and Africa Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales by Country (2020-2025) & (K Units)
 Table 47. Middle East and Africa Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales by Country (2026-2031) & (K Units)
 Table 48. Middle East and Africa Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue by Country (2020-2025) & (US$ Million)
 Table 49. Middle East and Africa Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue by Country (2026-2031) & (US$ Million)
 Table 50. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales (K Units) by Type (2020-2025)
 Table 51. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales (K Units) by Type (2026-2031)
 Table 52. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales Market Share by Type (2020-2025)
 Table 53. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales Market Share by Type (2026-2031)
 Table 54. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue (US$ Million) by Type (2020-2025)
 Table 55. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue (US$ Million) by Type (2026-2031)
 Table 56. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue Market Share by Type (2020-2025)
 Table 57. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue Market Share by Type (2026-2031)
 Table 58. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Price (US$/Unit) by Type (2020-2025)
 Table 59. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Price (US$/Unit) by Type (2026-2031)
 Table 60. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales (K Units) by Application (2020-2025)
 Table 61. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales (K Units) by Application (2026-2031)
 Table 62. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales Market Share by Application (2020-2025)
 Table 63. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales Market Share by Application (2026-2031)
 Table 64. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue (US$ Million) by Application (2020-2025)
 Table 65. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue (US$ Million) by Application (2026-2031)
 Table 66. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue Market Share by Application (2020-2025)
 Table 67. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue Market Share by Application (2026-2031)
 Table 68. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Price (US$/Unit) by Application (2020-2025)
 Table 69. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Price (US$/Unit) by Application (2026-2031)
 Table 70. Amoun Pharmaceuticals Company Information
 Table 71. Amoun Pharmaceuticals Description and Business Overview
 Table 72. Amoun Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 73. Amoun Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Product
 Table 74. Amoun Pharmaceuticals Recent Developments/Updates
 Table 75. EIPICO Company Information
 Table 76. EIPICO Description and Business Overview
 Table 77. EIPICO Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 78. EIPICO Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Product
 Table 79. EIPICO Recent Developments/Updates
 Table 80. Minapharm Pharmaceuticals Company Information
 Table 81. Minapharm Pharmaceuticals Description and Business Overview
 Table 82. Minapharm Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 83. Minapharm Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Product
 Table 84. Minapharm Pharmaceuticals Recent Developments/Updates
 Table 85. Pharco Pharmaceuticals Company Information
 Table 86. Pharco Pharmaceuticals Description and Business Overview
 Table 87. Pharco Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 88. Pharco Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Product
 Table 89. Pharco Pharmaceuticals Recent Developments/Updates
 Table 90. Alexion Pharmaceuticals Company Information
 Table 91. Alexion Pharmaceuticals Description and Business Overview
 Table 92. Alexion Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 93. Alexion Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Product
 Table 94. Alexion Pharmaceuticals Recent Developments/Updates
 Table 95. Alnylam Pharmaceuticals Company Information
 Table 96. Alnylam Pharmaceuticals Description and Business Overview
 Table 97. Alnylam Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 98. Alnylam Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Product
 Table 99. Alnylam Pharmaceuticals Recent Developments/Updates
 Table 100. Akari Therapeutics Company Information
 Table 101. Akari Therapeutics Description and Business Overview
 Table 102. Akari Therapeutics Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 103. Akari Therapeutics Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Product
 Table 104. Akari Therapeutics Recent Developments/Updates
 Table 105. Amgen Company Information
 Table 106. Amgen Description and Business Overview
 Table 107. Amgen Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 108. Amgen Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Product
 Table 109. Amgen Recent Developments/Updates
 Table 110. CSL Behring Company Information
 Table 111. CSL Behring Description and Business Overview
 Table 112. CSL Behring Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 113. CSL Behring Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Product
 Table 114. CSL Behring Recent Developments/Updates
 Table 115. Bioverativ Company Information
 Table 116. Bioverativ Description and Business Overview
 Table 117. Bioverativ Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 118. Bioverativ Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Product
 Table 119. Bioverativ Recent Developments/Updates
 Table 120. F. Hoffmann-La Roche Ltd Company Information
 Table 121. F. Hoffmann-La Roche Ltd Description and Business Overview
 Table 122. F. Hoffmann-La Roche Ltd Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 123. F. Hoffmann-La Roche Ltd Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Product
 Table 124. F. Hoffmann-La Roche Ltd Recent Developments/Updates
 Table 125. Novartis AG Company Information
 Table 126. Novartis AG Description and Business Overview
 Table 127. Novartis AG Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 128. Novartis AG Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Product
 Table 129. Novartis AG Recent Developments/Updates
 Table 130. Amgen Inc Company Information
 Table 131. Amgen Inc Description and Business Overview
 Table 132. Amgen Inc Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 133. Amgen Inc Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Product
 Table 134. Amgen Inc Recent Developments/Updates
 Table 135. Teva Pharmaceutical Company Information
 Table 136. Teva Pharmaceutical Description and Business Overview
 Table 137. Teva Pharmaceutical Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 138. Teva Pharmaceutical Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Product
 Table 139. Teva Pharmaceutical Recent Developments/Updates
 Table 140. Abbott Company Information
 Table 141. Abbott Description and Business Overview
 Table 142. Abbott Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 143. Abbott Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Product
 Table 144. Abbott Recent Developments/Updates
 Table 145. Key Raw Materials Lists
 Table 146. Raw Materials Key Suppliers Lists
 Table 147. Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Distributors List
 Table 148. Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Customers List
 Table 149. Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Trends
 Table 150. Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Drivers
 Table 151. Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Challenges
 Table 152. Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Restraints
 Table 153. Research Programs/Design for This Report
 Table 154. Key Data Information from Secondary Sources
 Table 155. Key Data Information from Primary Sources
 Table 156. Authors List of This Report


List of Figures
 Figure 1. Product Picture of Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment
 Figure 2. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Value Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Share by Type: 2024 & 2031
 Figure 4. Monoclonal Antibodies Therapy Product Picture
 Figure 5. Immunosuppressive Drugs Product Picture
 Figure 6. Hematopoietic Stem Cell Transplantation Product Picture
 Figure 7. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Value by Application (2020-2031) & (US$ Million)
 Figure 8. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Share by Application: 2024 & 2031
 Figure 9. Hospital
 Figure 10. Clinic
 Figure 11. Other
 Figure 12. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue, (US$ Million), 2020 VS 2024 VS 2031
 Figure 13. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Size (2020-2031) & (US$ Million)
 Figure 14. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales (2020-2031) & (K Units)
 Figure 15. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Average Price (US$/Unit) & (2020-2031)
 Figure 16. Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Report Years Considered
 Figure 17. Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales Share by Manufacturers in 2024
 Figure 18. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue Share by Manufacturers in 2024
 Figure 19. Global 5 and 10 Largest Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Players: Market Share by Revenue in Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment in 2024
 Figure 20. Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
 Figure 21. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Figure 22. North America Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales Market Share by Country (2020-2031)
 Figure 23. North America Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue Market Share by Country (2020-2031)
 Figure 24. United States Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 25. Canada Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 26. Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales Market Share by Country (2020-2031)
 Figure 27. Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue Market Share by Country (2020-2031)
 Figure 28. Germany Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 29. France Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 30. U.K. Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 31. Italy Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 32. Russia Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 33. Asia Pacific Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales Market Share by Region (2020-2031)
 Figure 34. Asia Pacific Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue Market Share by Region (2020-2031)
 Figure 35. China Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 36. Japan Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 37. South Korea Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 38. India Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 39. Australia Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 40. China Taiwan Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 41. Southeast Asia Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 42. Latin America Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales Market Share by Country (2020-2031)
 Figure 43. Latin America Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue Market Share by Country (2020-2031)
 Figure 44. Mexico Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 45. Brazil Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 46. Argentina Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 47. Middle East and Africa Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Sales Market Share by Country (2020-2031)
 Figure 48. Middle East and Africa Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue Market Share by Country (2020-2031)
 Figure 49. Turkey Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 50. Saudi Arabia Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 51. UAE Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 52. Global Sales Market Share of Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment by Type (2020-2031)
 Figure 53. Global Revenue Market Share of Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment by Type (2020-2031)
 Figure 54. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Price (US$/Unit) by Type (2020-2031)
 Figure 55. Global Sales Market Share of Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment by Application (2020-2031)
 Figure 56. Global Revenue Market Share of Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment by Application (2020-2031)
 Figure 57. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Price (US$/Unit) by Application (2020-2031)
 Figure 58. Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Value Chain
 Figure 59. Channels of Distribution (Direct Vs Distribution)
 Figure 60. Bottom-up and Top-down Approaches for This Report
 Figure 61. Data Triangulation
 Figure 62. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Accenture

SIMILAR REPORTS

Global Treatment of PNH Market Research Report 2024
Global Drugs for PNH Market Research Report 2024
Global PNH and aHUS Market Insights Forecast to 2030
Global Hemoglobinopathies Market Insights Forecast to 2030
Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Research Report 2025
Global Polycythemia Vera Treatment Drugs Market Research Report 2025
Hypoprothrombinemia Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Paraneoplastic Pemphigus Treatment Market Research Report 2025
Global Primary Hyperoxaluria Treatment Market Research Report 2025
Global Eculizumab Market Research Report 2024
Global Cryoglobulinemia Treatment Market Research Report 2025
Sickle cell Anemia Therapeutics Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global X Linked Hypophosphatemia Market Research Report 2024
Erythropoietic Protoporphyria EPP Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Thalassemia Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Phenylketonuria Treatment Product Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Phenylketonuria PKU Market Research Report 2025
Primary Myelofibrosis PMF Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Transfusion dependent Anemia Treatment Market Research Report 2025
Global Blood Tumor Treatment Market Research Report 2024

RELATED REPORTS

Global Insulin Coolers Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-19Z7671
Thu Sep 18 00:00:00 UTC 2025

Add to Cart

Global Ossicular Prostheses Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-10V14317
Thu Sep 18 00:00:00 UTC 2025

Add to Cart

Global Defibrillator Accessories Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-10O5919
Thu Sep 18 00:00:00 UTC 2025

Add to Cart

Global Septicemia Diagnostic Testing Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-4I19963
Thu Sep 18 00:00:00 UTC 2025

Add to Cart

Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions